Spyre Therapeutics prices follow-on stock offering at $350 million
SYRE•Spyre Therapeutics priced an underwritten public offering of 4,117,648 shares at $85 each, expecting gross proceeds of about $350 million. Underwriters have a 30-day option for up to about $52.5 million more.
1. Offering details
Spyre Therapeutics priced an underwritten public offering of 4,117,648 common shares at $85 per share, with gross proceeds expected to be about $350 million. Underwriters have a 30-day option to buy up to about $52.5 million in additional shares. The offering is expected to close on Oct. 7, 2026, subject to customary conditions. Net proceeds are earmarked to advance the company’s immunology pipeline, including late-stage development plans for SPY072 in hidradenitis suppurativa.
